#USA #Kessler Topaz #Radnor, PA #Investor Alert #uniQure N.V.

Investigation of uniQure N.V. by Kessler Topaz Meltzer & Check

In a recent announcement, the law firm Kessler Topaz Meltzer & Check, LLP has made it clear that they are investigating possible violations of federal securities laws affecting uniQure N.V. (NASDAQ: QURE) investors. This investigation is crucial for investors who may have incurred significant financial losses related to the company's stock performance.

Background of uniQure N.V.

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious diseases. Among their notable projects is AMT-130, a gene therapy aimed at treating Huntington's disease. However, on November 3, 2025, uniQure faced a significant setback when the FDA advised the company that the data submitted to support their Biologics License Application (BLA) was insufficient. This shocking announcement led to a notable decline in the company's stock price.

The Market Reaction

The market reacted swiftly to the news regarding the FDA’s assessment. Prior to the announcement on November 3, 2025, uniQure’s stock closed at $67.69. However, post-announcement, the stock plummeted by over 50%, closing at just $34.29. This drastic change signifies not only the market's loss of faith in the company’s current direction but also highlights the uncertainty surrounding the BLA submission process for the AMT-130 therapy. As per uniQure’s disclosure, they no longer have a clear timeline for submitting the application, adding to the unease felt by investors.

The Role of Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is actively investigating these developments to determine potential legal recourse for affected investors. The firm’s expertise in handling securities fraud cases makes them a reliable ally for investors impacted by this incident. They encourage any investors who believe they have suffered losses due to this situation to reach out to the firm. This includes both institutional and individual investors who may need assistance navigating the implications of this development.

How to Get Involved

If you are an investor in uniQure who has experienced severe losses and would like more information about your legal options, you can fill out an online form provided by Kessler Topaz Meltzer & Check. They can be contacted directly through Jonathan Naji, Esq. at (484) 270-1453 or via email. Potential claimants are encouraged to act swiftly, as time-sensitive matters could significantly affect their ability to recover losses.

Conclusion

As uniQure N.V. grapples with significant challenges regarding their drug application, investors must remain vigilant. The investigation by Kessler Topaz Meltzer & Check aims to assist those who have been adversely affected by the recent developments. Understanding your rights and options is imperative during such turbulent times in the stock market. Time could be of the essence, and the firm is determined to uphold the rights of investors throughout this process.

To learn more about the investigation and how you can participate, visit Kessler Topaz Meltzer & Check’s website.